Feature | January 22, 2007 | Amy Ballard, MEd

Shedding New Light On Ovarian Cancer

Fluorescent imaging illuminates as little as 0.3 mm.

Over the last 30 years, the mortality rate associated with ovarian cancer has only slightly decreased despite multiple efforts aimed at developing an effective method for its early detection, such as transvaginal ultrasound to visualize ovaries, measuring CA-125 levels and evaluating protein tumor-marker panels. In the U.S., approximately 16,210 women die from ovarian cancer every year and nearly 23,400 women are diagnosed annually, rendering it the most deadly gynecological disease.
The high death rate is attributable to the fact that 75 percent of diagnoses are made after the cancer has metastasized to other organs. Most women are diagnosed with advanced stage III or IV disease, and only 15 percent of these women survive for five years. Women who are diagnosed with stage I or II ovarian cancer have a 94 percent chance of a five-year survival. Clearly, establishing effective detection, staging and treatment methods are essential to combating this disease.
Despite the low success rate of early detection, researchers are optimistic that they will be able to reduce mortality rates using optical imaging in resecting tumors. Many times during debulking, small tumor implants are not detected in the peritoneal cavity and mesentery. The ability to accurately locate small tumor microfoci during surgery could improve tumor resection, which would better prevent intraperitoneal metastases. Avidin-FITC, a fluorescent imaging agent that binds to proteins expressed on the surface of many cancer cells, has been evaluated for its efficacy in allowing visualization of submillimeter tumor implants.
Image-guided conventional fluorescent imaging using the Maestro In Vivo Imaging System and the FLA-5100 from Fuji visualize implants as small as 0.3 mm. Once in-vivo fluorescent images were visualized with Maestro, in order to validate the size and tumor type of the in vivo images detected, the implants visualized were excised and examined using Fuji’s FLA-5100, which confirmed the size and tumor type. The test also showed that multiple lesions, all containing cancer cells, were visualized in vivo as small as 0.3 mm and the minimum detectable size was 0.1 mm. There were no false positives. Researchers expect that with optimal tumor resection, patients will respond more favorably to adjuvant therapies.

Related Content

Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
Sponsored Content | Videos | Breast Imaging | July 28, 2017
Nancy Cappello, Ph.D., executive director and founder of Are You Dense Inc. and Are You Dense Advocacy, explains how
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Kubtec Launches New Website For Digital Imaging and Irradiation Products
News | Digital Radiography (DR) | July 20, 2017
Kubtec announced the launch a new website focused on the applications of digital X-ray imaging and irradiation for...
Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017
News | Mammography | July 11, 2017
Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging...
Fujifilm Showcases Digital Radiography, Mammography Innovations at AHRA 2017
News | Digital Radiography (DR) | July 06, 2017
Fujifilm Medical Systems U.S.A. Inc. will present its comprehensive portfolio of digital radiography (DR) and...
Feature | Breast Density | July 05, 2017 | By Nancy M. Cappello, Ph.D.
Two decades of research on the masking risk of dense breast tissue by mammography screening is indisputable. As the...
Solis Mammography Ranks No. 19 in Dallas Business Journal’s Middle Market 50
News | Mammography | June 30, 2017
June 30, 2017 — Solis Mammography was named the 19th fastest-growing, middle-market company in North Texas by the
GE Healthcare Announces First U.S. Installation of Senographe Pristina Mammography System
News | Mammography | June 29, 2017
GE Healthcare has collaborated with Boca Raton Regional Hospital (Boca Raton, Fla.) to bring a more comfortable...
Overlay Init